PERATSIN

Main information

  • Trade name:
  • PERATSIN 4 mg coated tablet
  • Dosage:
  • 4 mg
  • Pharmaceutical form:
  • coated tablet
  • Prescription type:
  • Prescription only
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • PERATSIN 4 mg coated tablet
    Finland
  • Language:
  • English

Therapeutic information

  • Therapeutic area:
  • Perphenazine
  • Product summary:
  • Suitability for use in older adult patients Perphenazinum Avoid using in older persons. Slightly anticholinergic. Sedative. Risk of QT prolongation. Significant adverse effects include cognitive disorder, confusion, extrapyramidal symptoms, orthostatic hypotension, risk of cardiovascular events and risk of falls. Take several interactions into account. Non-pharmacological treatments are the first line approach in the management of behavioral and psychological symptoms of dementia. Weakens the efficacy of anti-Alzheimer`s drugs.

Status

  • Source:
  • Fimea
  • Authorization status:
  • Marketing authorization granted
  • Authorization number:
  • 1212
  • Authorization date:
  • 17-11-2008
  • Last update:
  • 21-02-2018